📣 VC round data is live. Check it out!

Pulmonx Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pulmonx and similar public comparables like Pangaea Oncology, BATM Advanced Communications, Tobii, Cyclopharm and more.

Pulmonx Overview

About Pulmonx

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.


Founded

1995

HQ

United States

Employees

291

Financials (LTM)

Revenue: $91M
EBITDA: ($33M)

EV

$60M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pulmonx Financials

Pulmonx reported last 12-month revenue of $91M and negative EBITDA of ($33M).

In the same LTM period, Pulmonx generated $68M in gross profit, ($33M) in EBITDA losses, and had net loss of ($52M).

Revenue (LTM)


Pulmonx P&L

In the most recent fiscal year, Pulmonx reported revenue of $90M and EBITDA of ($35M).

Pulmonx is unprofitable as of last fiscal year, with gross margin of 74%, EBITDA margin of (39%), and net margin of (60%).

See analyst estimates for Pulmonx
LTMLast FY202320242025202620272028
Revenue$91M$90M$69M$84M$90M
Gross Profit$68M$67M$51M$62M$67M
Gross Margin74%74%74%74%74%
EBITDA($33M)($35M)($55M)($51M)($49M)
EBITDA Margin(36%)(39%)(81%)(61%)(54%)
EBIT Margin(56%)(59%)(90%)(69%)(59%)
Net Profit($52M)($54M)($61M)($56M)($54M)
Net Margin(57%)(60%)(89%)(67%)(60%)

Financial data powered by Morningstar, Inc.

Pulmonx Stock Performance

Pulmonx has current market cap of $65M, and enterprise value of $60M.

Market Cap Evolution


Pulmonx's stock price is $1.55.

Pulmonx share price increased by 21.1% in the last 30 days, and decreased by 54.4% in the last year.

Pulmonx has an EPS (earnings per share) of $-1.28.

See more trading valuation data for Pulmonx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$60M$65M0.0%21.1%-1.9%-54.4%$-1.28

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pulmonx Valuation Multiples

Pulmonx trades at 0.7x EV/Revenue multiple, and (1.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Pulmonx

EV / Revenue (LTM)


Pulmonx Financial Valuation Multiples

As of May 26, 2026, Pulmonx has market cap of $65M and EV of $60M.

Pulmonx has a P/E ratio of (1.3x).

LTMLast FY202320242025202620272028
EV/Revenue0.7x0.7x0.9x0.7x0.7x
EV/EBITDA(1.8x)(1.7x)(1.1x)(1.2x)(1.2x)
EV/EBIT(1.2x)(1.1x)(1.0x)(1.0x)(1.1x)
EV/Gross Profit0.9x0.9x1.2x1.0x0.9x
P/E(1.3x)(1.2x)(1.1x)(1.2x)(1.2x)
EV/FCF(3.5x)(3.2x)(1.6x)(1.8x)(1.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pulmonx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pulmonx Margins & Growth Rates

Pulmonx grew revenue by 0% but EBITDA decreased by 16% in the last fiscal year.

In the most recent fiscal year, Pulmonx reported gross margin of 74%, EBITDA margin of (39%), and net margin of (60%).

See estimated margins and future growth rates for Pulmonx

Pulmonx Margins

Last FY202420252026202720282029
Gross Margin74%74%74%75%
EBITDA Margin(39%)(61%)(54%)(32%)
EBIT Margin(59%)(69%)(59%)(51%)
Net Margin(60%)(67%)(60%)(53%)
FCF Margin(21%)(39%)(36%)(16%)

Pulmonx Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth0%22%8%0%
Gross Profit Growth2%22%8%2%
EBITDA Growth(16%)(8%)(3%)(41%)
EBIT Growth(14%)(7%)(7%)(14%)
Net Profit Growth(11%)(7%)(4%)(11%)
FCF Growth(20%)(14%)(0%)(55%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Pulmonx Operational KPIs

Pulmonx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

Pulmonx's Rule of 40 is (32%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pulmonx's Rule of X is (31%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Pulmonx
LTMLast FY202320242025202620272028
Rule of 40(29%)(32%)
Bessemer Rule of X(18%)(31%)
Revenue per Employee$0.3M
Opex per Employee$0.4M
R&D Expenses to Revenue22%22%26%21%22%
Opex to Revenue133%164%143%133%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pulmonx Competitors

Pulmonx competitors include Pangaea Oncology, BATM Advanced Communications, Tobii, Cyclopharm, Xtant Medical, Klea, Daxor, Meditera, AnteoTech and SMAIO.

Most Pulmonx public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pangaea Oncology4.1x(62.9x)
BATM Advanced Communications0.4x0.5x2.7x4.0x
Tobii1.3x1.4x3.5x4.5x
Cyclopharm2.8x2.7x(5.7x)(5.5x)
Xtant Medical0.5x0.6x4.4x7.2x
Klea3.5x15.4x
Daxor6.1x7.2x
Meditera0.8x11.7x

This data is available for Pro users. Sign up to see all Pulmonx competitors and their valuation data.

Start Free Trial

Pulmonx Funding History

Before going public, Pulmonx raised $161M in total equity funding, across 3 rounds.


Pulmonx Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-20Series HAdage Capital Management; Ally Bridge Group; HealthQuest Capital; Partner Fund Management; Rock Springs Capital$66M
May-19Series GAlly Bridge Group; ArrowMark Partners; Boston Scientific; Driehaus Capital Management; Latterell Venture Partners; Montreux Equity Partners; RTW Investments$65MPulmonx Corporation, based in Redwood City, California, and Neuchâtel, Switzerland, develops diagnostic and therapeutic pulmonary device technologies for obstructive lung disease, particularly severe emphysema/COPD. Its key product, the Zephyr Valve, offers a minimally invasive treatment that improves quality of life, reduces shortness of breath, and increases activity levels without major surgery risks. The company markets this product in the US, Europe, Australia, and Asia, including China, positioning itself as a leader in interventional pulmonology. In May 2019, Pulmonx closed an oversubscribed $65 million financing round led by Ally Bridge Group, with participation from new investors RTW Investments, ArrowMark Partners, and Driehaus Capital Management, as well as existing investors such as Boston Scientific, Latterell Venture Partners, and Montreux Equity Partners. Charles Chon from Ally Bridge Group joined the board, and the company appointed Derrick Sung, Ph.D., as its new Chief Financial Officer to strengthen finance operations and strategic initiatives. The funds were intended to accelerate US commercialization efforts and drive global revenue growth for patients with severe emphysema. Ally Bridge Group highlighted Pulmonx's leading position and best-in-class team in interventional pulmonology, noting a renaissance in the US medtech sector with innovative technologies addressing unmet needs. Pulmonx's CEO Glen French emphasized partnering with ABG's experienced medtech investors to expand reach to over one million eligible patients worldwide. Post-round, Pulmonx continued advancing its global field leadership, culminating in a Nasdaq IPO in October 2020.
Jan-17Series FBoston Scientific$30M

Pulmonx M&A Activity

Pulmonx has acquired 1 company to date.

Last acquisition by Pulmonx was on January 8th 2015. Pulmonx acquired Aeris Therapeutics for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Pulmonx

Aeris Therapeutics
Description
Aeris Therapeutics is a Woburn, Massachusetts-headquartered developer of bronchoscopic therapies for emphysema patients. The company advances the Aerify Absorbable Lung Sealant, delivered via catheter to seal air leaks and improve lung function. With clinical trials completed in Europe and the U.S., Aeris targets advanced COPD treatments.
HQ CountryUnited States
HQ City
Boston, MA
Deal Date8 Jan 2015
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Pulmonx acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pulmonx

When was Pulmonx founded?Pulmonx was founded in 1995.
Where is Pulmonx headquartered?Pulmonx is headquartered in United States.
How many employees does Pulmonx have?As of today, Pulmonx has over 291 employees.
Who is the CEO of Pulmonx?Pulmonx's CEO is Glendon E. French.
Is Pulmonx publicly listed?Yes, Pulmonx is a public company listed on Nasdaq.
What is the stock symbol of Pulmonx?Pulmonx trades under LUNG ticker.
When did Pulmonx go public?Pulmonx went public in 2020.
Who are competitors of Pulmonx?Pulmonx main competitors include Pangaea Oncology, BATM Advanced Communications, Tobii, Cyclopharm, Xtant Medical, Klea, Daxor, Meditera, AnteoTech, SMAIO.
What is the current market cap of Pulmonx?Pulmonx's current market cap is $65M.
What is the current revenue of Pulmonx?Pulmonx's last 12 months revenue is $91M.
What is the current revenue growth of Pulmonx?Pulmonx revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Pulmonx?Current revenue multiple of Pulmonx is 0.7x.
Is Pulmonx profitable?No, Pulmonx is not profitable.
What is the current EBITDA of Pulmonx?Pulmonx has negative EBITDA and is not profitable.
What is Pulmonx's EBITDA margin?Pulmonx's last 12 months EBITDA margin is (36%).
What is the current EV/EBITDA multiple of Pulmonx?Current EBITDA multiple of Pulmonx is (1.8x).
What is the current FCF of Pulmonx?Pulmonx's last 12 months FCF is ($17M).
What is Pulmonx's FCF margin?Pulmonx's last 12 months FCF margin is (19%).
What is the current EV/FCF multiple of Pulmonx?Current FCF multiple of Pulmonx is (3.5x).
How many companies Pulmonx has acquired to date?As of May 2026, Pulmonx has acquired 1 company.
What was the largest acquisition by Pulmonx?None of the M&A deals Pulmonx has completed have disclosed valuations.
What companies Pulmonx acquired?Pulmonx acquired Aeris Therapeutics.
In how many companies Pulmonx has invested to date?Pulmonx hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Pulmonx

Lists including Pulmonx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial